← All trials
NCT04661358
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 5, 2021
- Primary completion
- Apr 30, 2027
- Completion date
- Apr 30, 2027
- First posted
- Dec 10, 2020
- Last posted
- Nov 19, 2021
- Enrollment
- 910
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Jaeb Center for Health ResearchLead sponsor
- RocheCollaborator
- National Institutes of Health (NIH)Study chair
- National Institutes of Health (NIH)Collaborator
- National Eye Institute (NEI)Collaborator
- Juvenile Diabetes Research FoundationCollaborator
- The Leona M. and Harry B. Helmsley Charitable TrustCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.